Vaxxinity logo

Vaxxinity(OTC) VAXX

Market Cap$14.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-90%
1 Month+0%
$0.00
+0.00%
+0.00Today
Vaxxinity last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-16
Vaxxinity stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-99.6%USD 0.032026-10-09
1 month+0%USD 0.002026-09-16
3 month+0%USD 0.002026-07-17
Year to date-66.67%USD 0.002025-12-31
1 year-90%USD 0.002025-10-16
3 year-99.99%USD 1.052023-10-17
Since inception-100%USD 16.552021-11-11

Vaxxinity Financials at a Glance

Market Cap

$14.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$56.94M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.00

Volume

3,937

Open

$0.03

Previous Close

$0.00

Daily Range

$0.00 - $0.03

52-Week Range

$0.00 - $0.20

Estimated Earnings Date

Aug 31, 2026

VAXX News

scientists examine cell make up microscope biotech

Why Shares of Vaxxinity Jumped This Week

James HalleyJan 19, 2023
Pharmaceutical factory worker

Why Shares of Vaxxinity Soared This Week

James HalleyDec 2, 2022
Shocked investor

Vaxxinity Has a Rough Public Debut

Brian Orelli, PhDNov 28, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vaxxinity

Vaxxinity, Inc. is a biotechnology company focused on developing innovative therapeutic candidates for neurological disorders and infectious diseases. Founded in 2014 and headquartered in Dallas, Texas, the company aims to address significant health challenges, particularly those related to coronaviruses and neurodegenerative conditions.

Products and Services
  • UB-311: Phase 2 candidate targeting Alzheimer's disease
  • UB-312: Investigational therapy for Parkinson's disease and related disorders
  • UB-612: Phase 3 candidate engineered to neutralize SARS-CoV-2
Growth Outlook
  • Pipeline includes multiple candidates in various stages of clinical trials
  • Focus on high-impact therapeutic areas presents significant market opportunities
  • Strong research and development investment supports future innovations
Financial Highlights
  • Recent quarterly net income of -$11.39 million reflects ongoing investment in R&D
  • Cash and short-term investments totaled $30.4 million as of Q4 2023
  • Current ratio of 1.89 indicates strong liquidity position
Vaxxinity, Inc. is positioned in the biotechnology sector, with a focus on addressing unmet medical needs through its innovative product pipeline. The company's commitment to research and development is evident in its substantial investments, which have resulted in several promising candidates targeting critical health issues. The recent financial data highlights a significant cash position, providing the company with the necessary resources to continue its development efforts. The current ratio indicates a solid liquidity position, which is essential for sustaining operations and funding future projects. Overall, Vaxxinity represents a compelling opportunity for investors interested in the biotechnology field, particularly in the areas of neurological disorders and infectious diseases.
AI Generated • Oct 8, 2026

Industry

Biotechnology

Sector

Health Care

Employees

57

CEO

Mei Mei Hu

Website

www.vaxxinity.com

Headquarters

Merritt Island, FL 32953, US

VAXX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-0.15%

Return on Capital

-203.96%

Return on Assets

-0.13%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

140.66M

Volume

3.94K

Avg. Volume

6.71K

Financials (TTM)

Gross Profit

-$2.23M

Operating Income

-$58.33M

EBITDA

-$54.01M

Operating Cash Flow

-$57.24M

Capital Expenditure

-$803.00K

Free Cash Flow

-$58.04M

Cash & ST Invst.

$30.40M

Total Debt

$15.17M

Vaxxinity Performance Analysis

Vaxxinity annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 66,000N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
Vaxxinity sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31N/A
Q22023-06-30N/A
Q32023-09-30N/A
Q42023-12-31N/A
Vaxxinity annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.09N/A
20222022-12-31USD -0.60-45.4%
20232023-12-31USD -0.45-24.7%
Vaxxinity sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-316.3%
Q22023-06-3026.7%
Q32023-09-309.1%
Q42023-12-3110.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$456.00K

+15.6%

Gross Margin

0.00%

N/A

Market Cap

$14.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$247.37

N/A

Employees

57

N/A

Net Income

-$11.39M

+44.4%

EBITDA

-$10.75M

+45.3%

Quarterly Fundamentals

Name
Q4 2023YOY CHG

Total Cash

$30.40M

-65.0%

Total Debt

$15.17M

+4.3%

Accounts Receivable

$414.00K

+0.0%

Inventory

$0.00

-100.0%

Long Term Debt

$13.26M

+1.7%

Short Term Debt

$1.91M

+26.7%

Return on Assets

-0.13%

N/A

Return on Invested Capital

-2.18%

N/A

Free Cash Flow

-$12.26M

+17.0%

Operating Cash Flow

-$11.85M

+18.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QBIOQ BioMed Inc.
$0.00-0.00%
HLUNHEALTHeUNIVERSE, Inc.
$0.00+0.00%
NNLXNanoLogix, Inc.
$0.00+0.00%
INFIQInfinity Pharmaceuticals, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$10.64-11.41%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$49.23+12.81%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.90+7.64%

Questions About VAXX

What is the current price of Vaxxinity?

Vaxxinity is trading at $0.00 per share.

What is the 52-week range for Vaxxinity?

Over the past 52 weeks, Vaxxinity has traded between $0.00 and $0.20.

How much debt does Vaxxinity have?

As of the most recent reporting period, Vaxxinity reported total debt of $15.17M.

How much cash does Vaxxinity have on hand?

Vaxxinity reported $5.04M in cash and cash equivalents in its most recent financial results.

What is Vaxxinity’s dividend yield?

Vaxxinity does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services